A 46-year-old Chinese woman presenting with retroperitoneal follicular dendritic cell sarcoma: a case report by Taize Yuan et al.
JOURNAL OF MEDICAL
CASE REPORTS
Yuan et al. Journal of Medical Case Reports 2014, 8:113
http://www.jmedicalcasereports.com/content/8/1/113CASE REPORT Open AccessA 46-year-old Chinese woman presenting with
retroperitoneal follicular dendritic cell sarcoma:
a case report
Taize Yuan, Qiuxiang Yang, Huanhuan Zhang, Jian Li and Xiuping Zhang*Abstract
Introduction: Follicular dendritic cells are non-phagocytic, non-lymphoid cells of the immune system that are
necessary for antigen presentation and the regulation of reactions in the germinal centers of the lymph nodes.
Follicular dendritic cell sarcoma is an unusual cancer, particularly in the intra-abdominal region. In the present report
we describe an unusual case of retroperitoneal follicular dendritic cell sarcoma that emphasizes the difficulty of
diagnosing and treating this tumor. Retroperitoneal follicular dendritic cell sarcoma has only been rarely reported in
the literature to date.
Case presentation: A 46-year-old Chinese woman of Han ethnicity presented with chronic right lower quadrant
abdominal pain over the preceding 4 weeks. The tumor was resected and submitted to histopathological
examination. The case was verified as retroperitoneal follicular dendritic cell sarcoma by microscopic examination and
immunohistochemical analysis. After diagnosis, she received postoperative radiotherapy and chemotherapy. She has
survived 3 years postoperatively, although she has a pulmonary metastasis.
Conclusions: Retroperitoneal follicular dendritic cell sarcoma may demonstrate aggressive potential. This study
indicated that postoperative adjuvant radiotherapy and chemotherapy could extend the survival of a patient with
retroperitoneal follicular dendritic cell sarcoma.
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Follicular dendritic cells (FDCs) are among the accessory
cells of the lymphoid system. Their main function is to
trap and present antigens and immune complexes to B
cells. FDCs are found mainly in the germinal centers of
the lymphoid tissue, where they form a tight meshwork.
FDCs feature complement receptors and human leukocyte
antigen-DR on their surfaces [1,2]. Lymphoid follicles are
found in the lymph nodes and in extranodal lymphoid tis-
sue [3]. Follicular dendritic cell sarcoma (FDCS), which
was first reported by Monda et al. [1] in 1986, is a rare
neoplastic proliferation that exhibits the morphological
and immunophenotypic features of FDCS. To date, ap-
proximately 106 cases of FDCS have been reported in the
literature, of which 46 occurred intra-abdominally [4]. We* Correspondence: xiupingzhang67@163.com
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the difficulty of diagnosing and treating this tumor.
Case presentation
A 46-year-old Chinese woman of Han ethnicity pre-
sented with a 4-week history of chronic right lower
quadrant abdominal pain without other associated
symptoms. A general systemic examination was normal
except for a large mass in her right lower quadrant.
There was no significant past medical history. Routine
biochemical and hematological tests were within nor-
mal limits. A chest X-ray also revealed no abnormalities.
A subsequent abdominal computed tomography (CT)
scan revealed a 8.6×6.0cm oval-shaped mass, with a clear
boundary and mild-moderate enhancement, in her lower
right retroperitoneal region, pressing against her right
psoas muscle and her right iliac artery (Figure 1A).
She underwent an operation to resect the mass. Surgical
exploration revealed a retroperitoneal mass measuringd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Computed tomography images of retroperitoneal follicular dendritic cell sarcoma. A: Contrast-enhanced computed tomography
scan of the abdomen revealing an 8.6cm retroperitoneal mass (arrow); B: liquid dark area (arrow) observed in the surgical area after operation;
C: significant shrinking of the liquid dark area (arrow) was observed after adjuvant therapy.
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muscle and her vertebral column and covering her inferior
vena cava. No associated lymphadenopathy was observed.
Because the mass had infiltrated her right psoas muscle
and was attached to her right iliac artery and her inferior
vena cava, most of the gross tumor was resected, and the
margin was positive. A CT scan revealed a liquid dark area
in the surgical area after the operation (Figure 1B).
A cut section revealed a homogenous solid mass with
a rough surface. Multiple sections were taken from various
areas of the tumor. Microscopic examination revealed that
the tumor was composed of fat to long spindle cells with
multinodular infiltration that were arranged in a storiform
pattern (Figure 2). The tumor exhibited necrosis, cellFigure 2 Microscopic appearance of the retroperitoneal
follicular dendritic cell sarcoma. The histopathological appearance
indicates that the tumor is composed of spindle cells arranged in a
storiform pattern and that these spindle cells are admixed with
lymphocytes (hematoxylin and eosin stain, ×100).atypia and obvious mitosis. The mitotic events numbered
up to 12 per 10 high-powered fields, and there was focally
marked nuclear atypia, including pleomorphic, multinu-
cleated cells. Furthermore, the tumor cells exhibited posi-
tive immunohistochemical staining for vimentin, CD21,
CD35, D2-40 and leukocyte common antigen (Figure 3A
to 3E) as well as negative staining for cytokeratin
(Figure 3F), CD20, CD30, CD117, epithelial membrane
antigen and S-l00 (not shown). Based on these histopatho-
logical and immunohistochemical findings, the patient
was diagnosed with FDCS of the retroperitoneal lymph
node.
She received postoperative sequential chemotherapy
and radiotherapy. Three cycles of chemotherapy with a
standard dose of cyclophosphamide, doxorubicin, vincris-
tine and prednisone (CHOP) were initiated in July 2010.
A total radiation dose of 60Gy was then administered over
6 weeks, followed by another three cycles of chemother-
apy with CHOP. To evaluate the efficacy of the adjuvant
therapy, an abdominal CT scan was performed, which re-
vealed that the liquid dark area had shrunk significantly
(Figure 1C).
Hospital records indicate that the patient has reached
3 years of follow-up. Although she is alive, she has a right
pulmonary metastasis.
Discussion
FDCS is a rare tumor that originates in the germinal cen-
ters of the lymph nodes in FDCS and has low malignant
potential. Monda et al. [1] first described the malignant
neoplasm in 1986. FDCS occurs mainly in adults; the aver-
age age is 47 years (14 to 77 years). The incidence rate is
the same for men and women [5]. The most common
Figure 3 Immunohistochemical features of retroperitoneal follicular dendritic cell sarcoma (paraffin immunohistochemical stain×400).
A: Positive immunohistochemical staining for vimentin; B: Positive immunohistochemical staining for CD21; C: Positive immunohistochemical
staining for CD35; D: Positive immunohistochemical staining for D2-40; E: Positive immunohistochemical staining for leukocyte common antigen;
F: Negative immunohistochemical staining for cytokeratin.
Yuan et al. Journal of Medical Case Reports 2014, 8:113 Page 3 of 4
http://www.jmedicalcasereports.com/content/8/1/113clinical symptom is a painless and slow-growing lymph
node. FDCS is found mostly in the lymph nodes, parti-
cularly the cervical lymph nodes and occasionally in the
axillary and mediastinal lymph nodes. FDCS is also occa-
sionally found outside the lymph nodes. Extranodal FDCS
has been found in the tonsils, nasopharynx, liver, spleen
and gastrointestinal tract [3,6-9].
Pathological diagnosis is challenging [10] and may re-
quire a combination of morphological, immunophenoty-
pical, cytochemical and electronmicroscopic analyses [2].
FDCS may be suspected if the tumor exhibits distinct
microscopic features, such as a storiform arrangement
of spindle-shaped cells, indistinct cell borders and a
background of lymphocytes scattered throughout the
neoplastic cells [11]. The morphology of our case is typ-
ical of FDCS, although various studies have reported
atypical presentations in the form of a multifocal disease,
increased mitosis, giant cell transformation and wide areas
of necrosis. To confirm the tumor, immunohistochemical
staining is required to detect the most widely used FDC
markers, including CD21, CD35, vimentin and D2-40,
which can distinguish FDCS from other spindle cell neo-
plasms [11,12]. S-100 and certain vascular or muscular
markers may also help to distinguish this tumor from
other tumors, such as malignant peripheral nerve sheath
tumors and gastrointestinal stromal tumors [13].
A complete surgical excision is the appropriate initial
therapy [3]. Adjuvant radiotherapy or chemotherapy
appears to be indicated in cases of incompletelyresected lesions or adverse pathological features during
recurrence [14]. However, because of the rarity of the
lesion and the retrospective nature of the published li-
terature, the role of adjuvant therapy (radiotherapy or
chemotherapy) remains unclear. A few recent reports
have suggested that FDCS should be viewed as an
intermediate-grade malignancy that presents a substan-
tial risk of metastasis to the lung, liver, intra-abdominal
soft tissues and lymph nodes [11,15].
Conclusions
As in this patient, retroperitoneal FDCS may demon-
strate aggressive potential. This study indicated that
postoperative adjuvant radiotherapy and chemotherapy
could extend the survival of a patient with retroperitoneal
FDCS.
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